These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 23943181)
1. Reversible ageusia associated with romidepsin therapy. Cooper MR; Brewer S; Broketa G Am J Health Syst Pharm; 2013 Sep; 70(17):1502-5. PubMed ID: 23943181 [TBL] [Abstract][Full Text] [Related]
2. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094 [TBL] [Abstract][Full Text] [Related]
3. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027 [TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Foss F; Duvic M; Lerner A; Waksman J; Whittaker S Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428 [TBL] [Abstract][Full Text] [Related]
5. Romidepsin: in the treatment of T-cell lymphoma. Yang LP Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508 [TBL] [Abstract][Full Text] [Related]
6. Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin. Kiewe P; Jovanovic S; Thiel E; Korfel A Ann Pharmacother; 2004; 38(7-8):1212-4. PubMed ID: 15161947 [TBL] [Abstract][Full Text] [Related]
7. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Lyseng-Williamson KA; Yang LP Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664 [TBL] [Abstract][Full Text] [Related]
8. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175 [TBL] [Abstract][Full Text] [Related]
9. Romidepsin for the treatment of T-cell lymphomas. McGraw AL Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158 [TBL] [Abstract][Full Text] [Related]
10. Romidepsin for the treatment of cutaneous T-cell lymphoma. Campas-Moya C Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671 [TBL] [Abstract][Full Text] [Related]
11. Romidepsin for cutaneous T-cell lymphoma. Prince HM; Dickinson M Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155 [TBL] [Abstract][Full Text] [Related]
12. The discovery and development of romidepsin for the treatment of T-cell lymphoma. Smolewski P; Robak T Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053 [TBL] [Abstract][Full Text] [Related]
13. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723 [TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity to romidepsin. Kakar R; Rommel J; McKinley-Grant L; Shenoy AG; DeSimone JA J Am Acad Dermatol; 2014 Jan; 70(1):e21-2. PubMed ID: 24355282 [No Abstract] [Full Text] [Related]
16. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Kim M; Thompson LA; Wenger SD; O'Bryant CL Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522 [TBL] [Abstract][Full Text] [Related]
17. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479 [TBL] [Abstract][Full Text] [Related]
18. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases. Poligone B; Rubio-Gonzalez B; Querfeld C Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384 [TBL] [Abstract][Full Text] [Related]
19. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin. Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207 [TBL] [Abstract][Full Text] [Related]